Collectively, the rising prevalence of MASLD, ALD and MetALD has made these conditions the fastest-growing cause of HCC and among the leading reason for liver transplantation worldwide (Ochoa-Allemant et al., 2025
For patients with type 2 diabetes or obesity who are interested in GLP-1 therapies, discuss the currently licensed options with your GP, practice nurse, or diabetes specialist nurse
Yes, and the two often work better together
And that brings us to the next issuehealth care costs
Our providers conduct comprehensive assessments to ensure safety and appropriateness before initiating any GLP1 therapy
Together, they aim to introduce new products tailored to individual patient needs, showing the industry's focus on targeted treatment approaches